Abstract: An automated biologic sample extracting system from a set of biological samples with a small footprint with minimal movement of the set of consumables, thereby reducing potential contamination during the extraction process. The extracting system comprising a set of reaction tubes, a storage unit to store a set of consumables; a sample preparation unit; a sample extraction unit; a waste unit; a plurality of robots to move tubes, samples, and boxes, and a programmable control system programmed to process samples in a serial pattern in which a series of samples follow one another to be processed in a time sequence and in succession so that it keeps a fixed processing turnaround time of each sample no matter when a sample would start the process.

Abstract: The present random access PCR reactor for biological analysis, comprises of a number of PCR reactors held on a platform, and one optical system to be shared by all of the PCR reactors on the platform. The optical system is held on a traverse mechanism to move it over any one of the PCR reactors that are ready to be imaged. Other PCR reactors on the platform can be accesses and replaced. The optical system has a lightpipe and a lightguide that distributes a uniform light over all the samples held on the reactor. The lightguide of the present optical system has a set of light reflecting structures that are strategically located to uniformly reflect an incoming light towards all the samples held in the PCR reactor that is being tested.

Abstract: An automated biologic sample extracting system from a set of biological samples with a small footprint with minimal movement of the set of consumables, thereby reducing potential contamination during the extraction process. The extracting system comprising a set of reaction tubes, a storage unit to store a set of consumables; a sample preparation unit; a sample extraction unit; a waste unit; a plurality of robots to move tubes, samples, and boxes, and a programmable control system programmed to process samples in a serial pattern in which a series of samples follow one another to be processed in a time sequence and in succession so that it keeps a fixed processing turnaround time of each sample no matter when a sample would start the process.

Abstract: This invention relates to the discovery that both non-particle and particle associated nucleic acids are present in blood plasma and serum and can be used to evaluate disease conditions.

Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclampsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin ? subunit (hCG-?), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.

Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclampsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin ? subunit (hCG-?), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.

Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclaimpsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin ? subunit (hCG-?), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.

Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclaimpsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin ? subunit (hCG-?), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.

Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclaimpsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin &bgr; subunit (hCG-&bgr;), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.

Abstract: This invention relates to the discovery that both non-particle and particle associated nucleic acids are present in blood plasma and serum and can be used to evaluate disease conditions.